menu

Overactive Bladder Market

Schedule Call

Overactive Bladder Market

Overactive Bladder Market By Disease Type (Idiopathic Overactive Bladder and Neurogenic Overactive Bladder), By Type (Diagnosis and Treatment) - Global Outlook & Forecast 2022-2030

GR - 635325 Category: Pharmaceuticals

Number of pages: 100  |  Report Format: PDF  |  Published date: November 18, 2022

Historical Years – 2020  |  Base Year – 2021  |  Forecasted Years – 2022-2030


Overactive Bladder Market Scope

Report Attribute

Details

Market size value in 2021

US$ 8.3 billion

Revenue forecast in 2030

US$ 12.33 billion

Growth Rate

CAGR of 4.5% from 2022 to 2030

Base year for estimation

2021

Forecast period

2022-2030

Segments covered

disease type, type, and region.

Regional scope

North America, Europe, Asia Pacific, and the Rest of the World (ROW)

Report Overview

The global overactive bladder market was pegged at ~US$ 8.3 billion in 2021 and is expected to witness a CAGR of 4.5% during the forecast period.

Market Fundamentals

The term "overactive bladder" (OAB) refers to a collection of urine symptoms. It's not an illness. Urinary impulses or needs that appear suddenly and without warning are the most typical sign. Treatments for overactive bladder are used to address the abrupt, involuntary contraction of the muscle in the urinary bladder wall that causes nocturia, frequency, urge incontinence, and urine urgency.

[6387432]

Market Dynamic

An increase in the elderly population and rising public knowledge of the therapies for overactive bladder syndrome are the two main factors driving market expansion for overactive bladder therapy. The overactive bladder treatment market is anticipated to rise as a result of increased investment in the development of novel medications and devices.

The development of unpleasant side effects related to the recommended medication or treatment is the main barrier to the overactive bladder therapies industry. However, market expansion is expected to be constrained by issues like product recalls and societal stigma.

Market Ecosystem

The global overactive bladder market has been analyzed from three perspectives, disease type, type, and region.

Overactive bladder Market by Disease Type

[2749234]

Based on disease type, the global overactive bladder market has been subdivided into, idiopathic overactive bladder and neurogenic overactive bladder. Due to the higher prevalence of idiopathic overactive bladder disorders, the segment for idiopathic overactive bladder syndrome accounted for a larger market share. Additionally, it is anticipated that increased use of SNM therapy for patients with idiopathic overactive bladder will aid in segmental growth.

Overactive Bladder Market by Type

Based on type, the global overactive bladder market has been divided into diagnosis and treatment. The diagnosis segment is further divided into, urine tests, bladder scans, cystoscopy, and others. The treatment segment is further divided into anticholinergics, mirabegron, neurostimulation, intravesical instillation, and others. In the overactive bladder market, anticholinergics enjoy a considerable market share as the first choice of medications for the treatment of overactive bladder syndrome.

Overactive Bladder Market by Region 

Based on region, the global overactive bladder market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World. The prevalence of individuals with overactive bladder in the US and the favorable reimbursement rules for the available treatments are just two of the factors contributing to the North American region's supremacy. Additionally, the desire of market players along with ANDA and FDA approval for various treatments is accelerating the market's expansion in the area.

Competitive Landscape

Some of the prominent players operating in the global overactive bladder market are: - 

  • Astellas Pharma, Inc.
  • Laborie
  • Teva Pharmaceutical Industries Ltd.
  • Macleods Pharmaceuticals Ltd.
  • Sanofi
  • Pfizer Inc.
  • Endo International Plc
  • AbbVie Inc.
  • Johnson & Johnson Services, Inc.
  • Urovant Sciences
  • Uro Medical
  • Hisamitsu Pharmaceutical Co., Inc.
  • Other Notable Players 

Strategic Developments

  • Urovant Sciences, Inc. and Thinx, Inc. establish a special relationship in November 2022 with the goal of educating people who experience the signs and symptoms of an overactive bladder.
  • The U.S. Food and Drug Administration granted Myrbetriq approval in March 2021 to treat neurogenic detrusor overactivity (NDO), a bladder malfunction brought on by neurological disability, in children three years of age and older.

Frequently Asked Questions About This Report

The global overactive bladder market is expected to grow at a CAGR of % in the forecast period.

Astellas Pharma, Teva Pharmaceuticals, Pfizer Inc., AbbVie Inc. etc. are a few key players in the global overactive bladder market.

The idiopathic overactive bladder segment dominates the global overactive bladder market.

Asia Pacific region is expected to witness the highest global overactive bladder market growth in the forecast period.

Table of Content

  1. INTRODUCTION
    1. Market Ecosystem 
    2. Timeline Under Consideration
      1. Historical Years – 2020
      2. Base Year – 2021
      3. Forecasted Years – 2022 to 2031
    3. Currency Used in the Report
  2. RESEARCH METHODOLOGY 
    1. Research Approach
    2. Data Collection Methodology
    3. Data Sources
      1. Secondary Sources 
      2. Primary Sources 
    4. Market Estimation Approach
      1. Bottom Up 
      2. Top Down 
    5. Market Forecasting Model
    6. Limitations and Assumptions       
  3. PREMIUM INSIGHTS
    1. Current Market Trends (COVID-19 Perspective)
    2. Key Players & Competitive Positioning (2021) 
  4. MARKET DYNAMICS
    1. Drivers
    2. Restraints/Challenges
    3. Opportunities
  5. GLOBAL OVERACTIVE BLADDER MARKET - ANALYSIS & FORECAST, BY DISEASE TYPE
    1. Idiopathic Overactive Bladder
    2. Neurogenic Overactive Bladder
  6. GLOBAL OVERACTIVE BLADDER MARKET - ANALYSIS & FORECAST, BY TYPE
    1. Diagnosis
      1. Urine Test
      2. Bladder Scan
      3. Cystoscopy
      4. Others
    2. Treatment
      1. Anticholinergics
      2.  Mirabegron
      3.  Neurostimulation
      4. Intravesical Instillation
      5. Others
  7. GLOBAL OVERACTIVE BLADDER MARKET - ANALYSIS & FORECAST, BY REGION
    1. North America Overactive Bladder Market
      1. North America Overactive Bladder Market, by Disease Type
      2. North America Overactive Bladder Market, by Type
      3. North America Overactive Bladder Market, by Country
        1. U.S.
          1. U.S. Overactive Bladder Market, by Disease Type
          2. U.S. Overactive Bladder Market, by Type
        2. Canada
          1. Canada Overactive Bladder Market, by Disease Type
          2. Canada Overactive Bladder Market, by Type
    2. Europe Overactive Bladder Market
      1. Europe Overactive Bladder Market, by Disease Type
      2. Europe Overactive Bladder Market, by Type
      3. Europe Overactive Bladder Market, by Country/Region
        1. Germany
          1. Germany Overactive Bladder Market, by Disease Type
          2. Germany Overactive Bladder Market, by Type
        2. U.K.
          1. U.K. Overactive Bladder Market, by Disease Type
          2. U.K. Overactive Bladder Market, by Type
        3. Spain
          1. Spain Overactive Bladder Market, by Disease Type
          2. Spain Overactive Bladder Market, by Type
        4. Italy 
          1. Italy Overactive Bladder Market, by Disease Type
          2. Italy Overactive Bladder Market, by Type
        5. France
          1. France Overactive Bladder Market, by Disease Type
          2. France Overactive Bladder Market, by Type
        6. Rest of Europe 
          1. Rest of Europe Overactive Bladder Market, by Disease Type
          2. Rest of Europe Overactive Bladder Market, by Type
    3. Asia Pacific Overactive Bladder Market
      1. Asia Pacific Overactive Bladder Market, by Disease Type
      2. Asia Pacific Overactive Bladder Market, by Type
      3. Asia Pacific Overactive Bladder Market, by Country/Region
        1. China
          1. China Overactive Bladder Market, by Disease Type
          2. China Overactive Bladder Market, by Type
        2. Japan
          1. Japan Overactive Bladder Market, by Disease Type
          2. Japan Overactive Bladder Market, by Type
        3. India
          1. India Overactive Bladder Market, by Disease Type
          2. India Overactive Bladder Market, by Type
        4. South Korea
          1. South Korea Overactive Bladder Market, by Disease Type
          2. South Korea Overactive Bladder Market, by Type
        5. Australia
          1. Australia Overactive Bladder Market, by Disease Type
          2. Australia Overactive Bladder Market, by Type
        6. Rest of Asia Pacific 
          1. Rest of Asia Pacific Overactive Bladder Market, by Disease Type
          2. Rest of Asia Pacific Overactive Bladder Market, by Type
    4. Rest of the World Overactive Bladder Market
      1. Rest of the World Overactive Bladder Market, By Region
        1. Rest of the World Overactive Bladder Market, by Disease Type
        2. Rest of the World Overactive Bladder Market, by Type
        3. Latin America
          1. Latin America Overactive Bladder Market, by Disease Type
          2. Latin America Overactive Bladder Market, by Type
        4. Middle East & Africa
          1. Middle East & Africa Overactive Bladder Market, by Disease Type
          2. Middle East & Africa Overactive Bladder Market, by Type
  8. COMPANY PROFILES              
    1. Astellas Pharma, Inc.
      1. Business Snapshot 
      2. Ingredient Procedures/Services Offered
      3. Financial Details*
      4. Strategic Developments
    2. Laborie
    3. Teva Pharmaceutical Industries Ltd.
    4. Macleods Pharmaceuticals Ltd.
    5. Sanofi
    6. Pfizer Inc.
    7. Endo International Plc
    8. AbbVie Inc.
    9. Johnson & Johnson Services, Inc.
    10. Urovant Sciences
    11. Uro Medical
    12. Hisamitsu Pharmaceutical Co., Inc.
    13. Other Notable Players

*Insights on financial permanence are subject to the availability of information in the public domain


Single User License
Single User License
Multi User License
Enterprise User License
$4,750.00
Provides access to one user only and should not be shared with other employees within the organization.
Provides access to up to five users within the department or an organization.
Provides access to all the employees in the organization. The report can also be shared with subsidiaries, sister concerns and group entities.
Grants user/users’ access to quantitative data only, which includes but is not restricted to numeric data, tables, and charts as defined by Growth+ Reports.
  • What are the significant driving and restraining factors for the Overactive Bladder Market?
  • Who are the leading companies in the market?
  • Where can you find the updates on recent developments by market players?
  • When is the right time to get discounts on complete market reports?
  • Why to invest in the Overactive Bladder Market?
  • How to improve your organizational performance?
  • How to shift customers towards your brand?

Recommended Reports